Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Compugen宣布，首位患者在Compugen授权给吉利德的针对IL-18结合蛋白的潜在首创抗体Com503的第一阶段临床试验中接受了给药。
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Compugen宣布，Compugen在1期临床试验中为首位患者服用了Compugen向吉利德许可的针对Il-18结合蛋白的潜在同类首创抗体
热门讨论
12月CPI数据助推降息预期，美股能否延续强势？
美国12月CPI同比上涨2.9%，符合预期，但已连续三个月呈现上涨趋势。市场对此反应积极，因为剔除食品和能源价格的核心CPI上涨了3.2%，是自2021年以来的最低读数之一。12月PPI增长3.3%，低于预期的3.5%。美联储目标在2025年实现2.5%的通胀率，但密歇根调查数据
In One Chart
01/15 22:05
这是十二月消费指数的详细情况，一览无余